Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial
- 15 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (16) , 3133-3140
- https://doi.org/10.1200/jco.2003.02.014
Abstract
Purpose: This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC).Keywords
This publication has 22 references indexed in Scilit:
- Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup TrialJournal of Clinical Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized StudyJournal of Clinical Oncology, 2001
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999
- Postoperative UFT Adjuvant and the Risk Factors for Recurrence in Renal Cell Carcinoma: A Long-Term Follow-Up StudyInternational Journal of Urology, 1997
- Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study groupInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinomaAmerican Journal of Clinical Oncology, 1982
- The Value of Radiotherapy in the Treatment of Hypernephroma-a Clinical TrialBritish Journal of Urology, 1973
- Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 casesCancer, 1971
- The Results of Radical Nephrectomy for Renal Cell CarcinomaJournal of Urology, 1969